Changeflow GovPing Healthcare & Life Sciences USPTO Patent Application: CD70 Antibody Drug Co...
Routine Notice Added Final

USPTO Patent Application: CD70 Antibody Drug Conjugates

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260083853A1) detailing CD70 antibody drug conjugates for treating cancer and autoimmune diseases. The application was filed on October 25, 2023, by inventors Xiao Shang and others.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a USPTO patent application (US20260083853A1) for "CD70 antibody drug conjugates and methods of using the same" for the treatment of cancer and autoimmune diseases. The application was filed on October 25, 2023, by inventors Xiao Shang, Haidong Liu, Julia Gavrilyuk, Baiteng Zhao, Tae Han, and Zhu Chen.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future developments in therapeutic agents and may be of interest to pharmaceutical and biotechnology companies for competitive intelligence and R&D strategy. No compliance actions or deadlines are associated with this filing.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME

Application US20260083853A1 Kind: A1 Mar 26, 2026

Inventors

Xiao SHANG, Haidong LIU, Julia GAVRILYUK, Baiteng ZHAO, Tae HAN, Zhu CHEN

Abstract

The present invention provides conjugates of CD70 antibodies, and/or antigen binding portions thereof, for use in the treatment of cancer and autoimmune disease.

CPC Classifications

A61K 47/68037 A61K 47/68031 A61K 47/6849 A61K 47/6851 A61K 47/6889 A61P 35/00 C07K 16/2875

Filing Date

2023-10-25

Application No.

19123878

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
October 25th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083853A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Therapeutic Treatment
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Cancer Treatment Autoimmune Disease Treatment Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!